4 recruiting, 2 not yet recruiting. 4 Phase 3, 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Not yet recruiting 2, Recruiting 2 |
| Phase 1 | 2 | Recruiting 2 |
| Phase 2 | 2 | Recruiting 2 |
Follow QLC5508: new trials by email Literature Review of QLC5508 trials Research Report on QLC5508
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study Comparing QLC5508 in Combination With QL2107 Versus Tislelizumab Plus Platinum-based Chemotherapy in Participants Wih Treatment-naïve Extensive-Stage Small Cell Lung Cancer QLC5508, QL2107, Tislelizumab - Extensive-stage Small Cell Lung Cancer | Phase 3 | Recruiting | Qilu Pharmaceutical Co., Ltd. | 556 | 2026-10-27 | 2026-10-30 |
| QLC5508 vs. Investigator's Choice Chemotherapy in Advanced Extrapulmonary Neuroendocrine Carcinoma Investigator's Choice Chemotherapy (FOLFIRI or FOLFOX regimen), QLC5508 - Extrapulmonary Neuroendocrine Carcinoma | Phase 3 | Not yet recruiting | Qilu Pharmaceutical Co., Ltd. | 270 | 2026-10-26 | 2026-10-26 |
| QLC5508 in Participants With Metastatic Prostate Cancer QLC5508, Docetaxel - Prostate Cancer | Phase 3 | Not yet recruiting | Qilu Pharmaceutical Co., Ltd. | 700 | 2026-06-20 | 2026-06-08 |
| QLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma QLC5508, Investigator's Choice of Chemotherapy (docetaxel, paclitaxel, or Irinotecan Hydrochloride) - Esophageal Squamous Cell Carcinoma (ESCC) | Phase 3 | Recruiting | Qilu Pharmaceutical Co., Ltd. | 466 | 2026-04-20 | 2026-04-24 |
| A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancer QLC5508, abiraterone acetate, enzalutamide - Advanced Prostate Cancer | Phase 1 / Phase 2 | Recruiting | Qilu Pharmaceutical Co., Ltd. | 212 | 2025-11-05 | 2026-06-02 |
| A Study of QLC5508 Combinations in Patients With Advanced Solid Tumors QLC5508, QL1706, Cisplatin/ Carboplatin - Advanced Solid Tumor | Phase 1 / Phase 2 | Recruiting | Qilu Pharmaceutical Co., Ltd. | 444 | 2025-10-24 | 2025-12-01 |
Esophageal Squamous Cell Carcinoma (1) · Prostatic Neoplasms (1) · Small Cell Lung Carcinoma (1)
Qilu Pharmaceutical Co., Ltd. (6)
China (4)